Updates in systemic treatment for metastatic cervical cancer

Current Treatment Options in Oncology

Volumn 15, Issue 1, 2014, Pages 1-13

  Chao, Angel ^a,b   Lin, Cheng Tao ^a,b   Lai, Chyong Huey ^a,b  

^a CHANG GUNG UNIVERSITY   (Taiwan)

^b CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

Author keywords

Angiogenesis; Bevacizumab; Cervical cancer; Cetuximab; Chemotherapy; Cisplatin; Clinical trials; Erlotinib; Gefitinib; Gemcitabine; Human papillomavirus; Ifosfamide; Immunotherapy; Inhibitor; Irinotecan; Lapatinib; Mitomycin C; Neoplasm; Paclitaxel; Pazopanib; Phase III trial; Platinum; Targeted therapies; Therapeutic; Topotecan; Tyrosine kinase; Vaccines; Vinorelbine

Indexed keywords

ANGIOGENESIS INHIBITOR; BEVACIZUMAB; CARBOPLATIN; CELECOXIB; CETUXIMAB; CISPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; ERLOTINIB; GEFITINIB; GEMCITABINE; IFOSFAMIDE; IPROPLATIN; IRINOTECAN; LAPATINIB; LC 9018; MITOMYCIN; NAVELBINE; PACLITAXEL; PAZOPANIB; PROTEIN TYROSINE KINASE INHIBITOR; SUNITINIB; TOPOTECAN; WART VIRUS VACCINE; Z 100;

ARTICLE; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CHEMORADIOTHERAPY; DRUG EFFICACY; HUMAN; METASTATIC CERVICAL CANCER; MOLECULARLY TARGETED THERAPY; MONOTHERAPY; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); SALVAGE THERAPY; SYSTEMIC THERAPY; UTERINE CERVIX CANCER;

FEMALE; HUMANS; NEOPLASM METASTASIS; UTERINE CERVICAL NEOPLASMS;

EID: 84891896489     PISSN: 15272729     EISSN: 15346277     Source Type: Journal    
DOI: 10.1007/s11864-013-0273-1     Document Type: Article

References (68)

1. Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin. 2011;61:69-90.
2. NCCN Clinical Practice Guidelines in Oncology. Cervical Cancer. Version I.2012. NCCN.org.
3. Green J, Kirwan J, Tierney J, et al. Concomitant chemotherapy and radiation therapy for cancer of the uterine cervix. Cochrane Database Syst Rev 2005:CD002225.
4. Leitao Jr MM, Chi DS. Recurrent cervical cancer. Curr Treat Options Oncol. 2002;3:105-11.
5. Lai CH. Management of recurrent cervical cancer. Chang Gung Med J. 2004;27:711-7.
6. Ho KC, Wang CC, Qiu JT, et al. Identification of prognostic factors in patients with cervical cancer and supraclavicular lymph node recurrence. Gynecol Oncol. 2011;123:253-6.
7. Qiu JT, Abdullah NA, Chou HH, et al. Outcomes and prognosis of patients with recurrent cervical cancer after radical hysterectomy. Gynecol Oncol. 2012;127:472-7.
8. Takano M, Kikuchi Y, Kita T, et al. Complete remission of metastatic and relapsed uterine cervical cancers using weekly administration of bevacizumab and paclitaxel/carboplatin. Onkologie. 2009;32:595-7.
9. Chao A, Ho KC, Wang CC, et al. Positron emission tomography in evaluating the feasibility of curative intent in cervical cancer patients with limited distant lymph node metastases. Gynecol Oncol. 2008;110:172-8.
10. Scatchard K, Forrest JL, Flubacher M, et al. Chemotherapy for metastatic and recurrent cervical cancer. Cochrane Database Syst Rev. 2012;10, CD006469. This review is a detailed analysis of different types and combinations of chemotherapy for the treatment of recurrent and metastatic cervical cancer.
11. Thigpen T, Shingleton H, Homesley H, et al. Cis-platinum in treatment of advanced or recurrent squamous cell carcinoma of the cervix: a phase II study of the Gynecologic Oncology Group. Cancer. 1981;48:899-903.
12. Bonomi P, Blessing JA, Stehman FB, et al. Randomized trial of three cisplatin dose schedules in squamous-cell carcinoma of the cervix: a Gynecologic Oncology Group study. J Clin Oncol. 1985;3:1079-85.
13. Zagouri F, Sergentanis TN, Chrysikos D, et al. Molecularly targeted therapies in cervical cancer. A systematic review. Gynecol Oncol. 2012;126:291-303. This review extensively covers the possible targeted therapies used in cervical cancer.
14. Leath 3rd CA, Straughn Jr JM. Chemotherapy for advanced and recurrent cervical carcinoma: results from cooperative group trials. Gynecol Oncol. 2013;129:251-7. This review is a comprehensive summary of recent trials of chemotherapy in metastatic cervical cancer.
15. McGuire 3rd WP, Arseneau J, Blessing JA, et al. A randomized comparative trial of carboplatin and iproplatin in advanced squamous carcinoma of the uterine cervix: a Gynecologic Oncology Group study. J Clin Oncol. 1989;7:1462-8.
16. Thigpen T, Blessing JA, Gallup DG, et al. Phase II trial of mitomycin-C in squamous cell carcinoma of the uterine cervix: a Gynecologic Oncology Group study. Gynecol Oncol. 1995;57:376-9.
17. Sutton GP, Blessing JA, Adcock L, et al. Phase II study of ifosfamide and mesna in patients with previously-treated carcinoma of the cervix. A Gynecologic Oncology Group study. Investig New Drugs. 1989;7:341-3.
18. Look KY, Blessing JA, Levenback C, et al. A phase II trial of CPT-11 in recurrent squamous carcinoma of the cervix: a gynecologic oncology group study. Gynecol Oncol. 1998;70:334-8.
19. Schilder RJ, Blessing JA, Morgan M, et al. Evaluation of gemcitabine in patients with squamous cell carcinoma of the cervix: a Phase II study of the gynecologic oncology group. Gynecol Oncol. 2000;76:204-7.
20. Bookman MA, Blessing JA, Hanjani P, et al. Topotecan in squamous cell carcinoma of the cervix: a phase II study of the Gynecologic Oncology Group. Gynecol Oncol. 2000;77:446-9.
21. McGuire WP, Blessing JA, Moore D, et al. Paclitaxel has moderate activity in squamous cervix cancer. A Gynecologic Oncology Group study. J Clin Oncol. 1996;14:792-5.
22. Muggia FM, Blessing JA, Method M, et al. Evaluation of vinorelbine in persistent or recurrent squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study. Gynecol Oncol. 2004;92:639-43.
23. Fiorica JV, Blessing JA, Puneky LV, et al. A phase II evaluation of weekly topotecan as a single agent second line therapy in persistent or recurrent carcinoma of the cervix: a Gynecologic Oncology Group study. Gynecol Oncol. 2009;115:285-9.
24. Schilder RJ, Blessing J, Cohn DE. Evaluation of gemcitabine in previously treated patients with non-squamous cell carcinoma of the cervix: a phase II study of the Gynecologic Oncology Group. Gynecol Oncol. 2005;96:103-7.
25. Curtin JP, Blessing JA, Webster KD, et al. Paclitaxel, an active agent in nonsquamous carcinomas of the uterine cervix: a Gynecologic Oncology Group Study. J Clin Oncol. 2001;19:1275-8.
26. Muggia FM, Blessing JA, Waggoner S, et al. Evaluation of vinorelbine in persistent or recurrent nonsquamous carcinoma of the cervix: a Gynecologic Oncology Group Study. Gynecol Oncol. 2005;96:108-11.
27. Rose PG, Blessing JA, Gershenson DM, et al. Paclitaxel and cisplatin as first-line therapy in recurrent or advanced squamous cell carcinoma of the cervix: a gynecologic oncology group study. J Clin Oncol. 1999;17:2676-80.
28. Fiorica J, Holloway R, Ndubisi B, et al. Phase II trial of topotecan and cisplatin in persistent or recurrent squamous and nonsquamous carcinomas of the cervix. Gynecol Oncol. 2002;85:89-94.
29. Brewer CA, Blessing JA, Nagourney RA, et al. Cisplatin plus gemcitabine in previously treated squamous cell carcinoma of the cervix: a phase II study of the Gynecologic Oncology Group. Gynecol Oncol. 2006;100:385-8.
30. Tiersten AD, Selleck MJ, Hershman DL, et al. Phase II study of topotecan and paclitaxel for recurrent, persistent, or metastatic cervical carcinoma. Gynecol Oncol. 2004;92:635-8.
31. IFG-01-0106: Study on Paclitaxel Plus Topotecan in Comparison With Topotecan Plus Cisplatin in Recurrent or Persistent Cervical Carcinoma (AGO-Zervix-1). http://clinicaltrials.gov/.
32. Omura GA, Blessing JA, Vaccarello L, et al. Randomized trial of cisplatin versus cisplatin plus mitolactol versus cisplatin plus ifosfamide in advanced squamous carcinoma of the cervix: a Gynecologic Oncology Group study. J Clin Oncol. 1997;15:165-71.
33. Bloss JD, Blessing JA, Behrens BC, et al. Randomized trial of cisplatin and ifosfamide with or without bleomycin in squamous carcinoma of the cervix: a gynecologic oncology group study. J Clin Oncol. 2002;20:1832-7.
34. Moore DH, Blessing JA, McQuellon RP, et al. Phase III study of cisplatin with or without paclitaxel in stage IVB, recurrent, or persistent squamous cell carcinoma of the cervix: a gynecologic oncology group study. J Clin Oncol. 2004;22:3113-9. This GOG 169 trial documented improved response rates for cisplatin plus paclitaxel in metastatic cervical cancer.
35. Long 3rd HJ, Bundy BN, Grendys Jr EC, et al. Randomized phase III trial of cisplatin with or without topotecan in carcinoma of the uterine cervix: a Gynecologic Oncology Group Study. J Clin Oncol. 2005;23:4626-33. This GOG 179 trial showed improved OS rates for cisplatin plus topotecan, which led to its addition to the GOG 204 trial.
36. Monk BJ, Sill MW, McMeekin DS, et al. Phase III trial of four cisplatin-containing doublet combinations in stage IVB, recurrent, or persistent cervical carcinoma: a Gynecologic Oncology Group study. J Clin Oncol. 2009;27:4649-55. The investigators in this GOG 204 trial found similarly low response rates and short OS rates for platinum doublets of paclitaxel, topotecan, vinorelbine, and gemcitabine. These results highlight the need to study other targeted therapies and biologic agents.
37. Kitagawa R, Katsumata N, Shibata T, et al. A randomized, phase III trial of paclitaxel plus carboplatin (TC) versus paclitaxel plus cisplatin (TP) in stage IVB, persistent or recurrent cervical cancer: Japan Clinical Oncology Group study (JCOG0505) J Clin Oncol. 2012; (Suppl; abstr 5006).
38. Tewari KS, Sill M, Long HJ, et al. Incorporation of bevacizumab in the treatment of recurrent and metastatic cervical cancer: a phase III randomized trial of the Gynecologic Oncology Group. J Clin Oncol. 2013; 31, (suppl; abstr 3). The findings of this study are important because they may change clinical practice and improve outcomes in patients with recurrent cervical cancer. Patients who received bevacizumab had significantly better OS rates than those who did not.
39. Tewari KS, Sill M, Monk B, et al. Phase III randomized clinical trial of cisplatin plus paclitaxel vs the non-platinum chemotherapy doublet of topotecan plus paclitaxel in women with recurrent, persistent, or advanced cervical carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol. 2013;130:e2.
40. Monk BJ, Sill MW, Burger RA, et al. Phase II trial of bevacizumab in the treatment of persistent or recurrent squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study. J Clin Oncol. 2009;27:1069-74.
41. Monk BJ, Mas Lopez L, Zarba JJ, et al. Phase II, open-label study of pazopanib or lapatinib monotherapy compared with pazopanib plus lapatinib combination therapy in patients with advanced and recurrent cervical cancer. J Clin Oncol. 2010;28:3562-9.
42. Mackay HJ, Tinker A, Winquist E, et al. A phase II study of sunitinib in patients with locally advanced or metastatic cervical carcinoma: NCIC CTG Trial IND.184. Gynecol Oncol. 2010;116:163-7.
43. Goncalves A, Fabbro M, Lhomme C, et al. A phase II trial to evaluate gefitinib as second- or third-line treatment in patients with recurring locoregionally advanced or metastatic cervical cancer. Gynecol Oncol. 2008;108:42-6.
44. Schilder RJ, Sill MW, Lee YC, et al. A phase II trial of erlotinib in recurrent squamous cell carcinoma of the cervix: a Gynecologic Oncology Group Study. Int J Gynecol Cancer. 2009;19:929-33.
45. Santin AD, Sill MW, McMeekin DS, et al. Phase II trial of cetuximab in the treatment of persistent or recurrent squamous or non-squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study. Gynecol Oncol. 2011;122:495-500.
46. Farley J, Sill MW, Birrer M, et al. Phase II study of cisplatin plus cetuximab in advanced, recurrent, and previously treated cancers of the cervix and evaluation of epidermal growth factor receptor immunohistochemical expression: a Gynecologic Oncology Group study. Gynecol Oncol. 2011;121:303-8.
47. Kurtz JE, Hardy-Bessard AC, Deslandres M, et al. Cetuximab, topotecan and cisplatin for the treatment of advanced cervical cancer: a phase II GINECO trial. Gynecol Oncol. 2009;113:16-20.
48. Herrera FG, Chan P, Doll C, et al. A prospective phase I-II trial of the cyclooxygenase-2 inhibitor celecoxib in patients with carcinoma of the cervix with biomarker assessment of the tumor microenvironment. Int J Radiat Oncol Biol Phys. 2007;67:97-103.
49. Gaffney DK, Winter K, Dicker AP, et al. A phase II study of acute toxicity for Celebrex (celecoxib) and chemoradiation in patients with locally advanced cervical cancer: primary endpoint analysis of RTOG 0128. Int J Radiat Oncol Biol Phys. 2007;67:104-9.
50. Chavez-Blanco A, Segura-Pacheco B, Perez-Cardenas E, et al. Histone acetylation and histone deacetylase activity of magnesium valproate in tumor and peripheral blood of patients with cervical cancer. A phase I study. Mol Cancer. 2005;4:22.
51. Albers AE, Kaufmann AM. Therapeutic human papillomavirus vaccination. Public Health Genom. 2009;12:331-42.
52. Bellati F, Napoletano C, Ruscito I, et al. Past, present and future strategies of immunotherapy in gynecological malignancies. Curr Mol Med. 2013;13:648-69.
53. Fujiwara K, Ohashi Y, Ochiai K, et al. Phase III placebo controlled double blind randomized trial of radiation therapy for stage 2B-4A cervical cancer with immunomodulator Z-100: JGOG-DT101 study. J Clin Oncol. 2013; (Suppl; abstr 5506).
54. Chen IJ, Yen CF, Lin KJ, et al. Vaccination with OK-432 followed by TC-1 tumor lysate leads to significant antitumor effects. Reprod Sci. 2011;18:687-94.
55. Kikkawa F, Kawai M, Oguchi H, et al. Randomised study of immunotherapy with OK-432 in uterine cervical carcinoma. Eur J Cancer. 1993;29A:1542-6.
56. Yamamoto K, Noda K, Hatae M, et al. Effects of concomitant use of doxifluridine, radiotherapy and immunotherapy in patients with advanced cervical cancer. Oncol Rep. 2001;8:273-7.
57. Okawa T, Niibe H, Arai T, et al. Effect of LC9018 combined with radiation therapy on carcinoma of the uterine cervix. A phase III, multicenter, randomized, controlled study. Cancer. 1993;72:1949-54.
58. Hung CF, Ma B, Monie A, et al. Therapeutic human papillomavirus vaccines: current clinical trials and future directions. Exp Opin Biol Ther. 2008;8:421-39.
59. Stern PL, van der Burg SH, Hampson IN, et al. Therapy of human papillomavirus-related disease. Vaccine. 2012;30 Suppl 5:F71-82.
60. Gunn GR, Zubair A, Peters C, et al. Two Listeria monocytogenes vaccine vectors that express different molecular forms of human papilloma virus-16 (HPV-16) E7 induce qualitatively different T cell immunity that correlates with their ability to induce regression of established tumors immortalized by HPV-16. J Immunol. 2001;167:6471-9.
61. Maciag PC, Radulovic S, Rothman J. The first clinical use of a live-attenuated Listeria monocytogenes vaccine: a Phase I safety study of Lm-LLO-E7 in patients with advanced carcinoma of the cervix. Vaccine. 2009;27:3975-83.
62. Petit RG, Basu P, Advaxis I, et al. ADXS11-001 immunotherapy targeting HPV-E7: preliminary survival data from a P2 study in Indian women with recurrent/refractory cervical cancer. J Clin Oncol. 2013; 31 (Abstract 5529).
63. Kaufmann AM, Stern PL, Rankin EM, et al. Safety and immunogenicity of TA-HPV, a recombinant vaccinia virus expressing modified human papillomavirus (HPV)-16 and HPV-18 E6 and E7 genes, in women with progressive cervical cancer. Clin Cancer Res. 2002;8:3676-85.
64. Ressing ME, van Driel WJ, Brandt RM, et al. Detection of T helper responses, but not of human papillomavirus-specific cytotoxic T lymphocyte responses, after peptide vaccination of patients with cervical carcinoma. J Immunother. 2000;23:255-66.
65. Kenter GG, Welters MJ, Valentijn AR, et al. Phase I immunotherapeutic trial with long peptides spanning the E6 and E7 sequences of high-risk human papillomavirus 16 in end-stage cervical cancer patients shows low toxicity and robust immunogenicity. Clin Cancer Res. 2008;14:169-77.
66. Welters MJ, Kenter GG, Piersma SJ, et al. Induction of tumor-specific CD4+ and CD8+ T-cell immunity in cervical cancer patients by a human papillomavirus type 16 E6 and E7 long peptides vaccine. Clin Cancer Res. 2008;14:178-87.
67. Ferrara A, Nonn M, Sehr P, et al. Dendritic cell-based tumor vaccine for cervical cancer II: results of a clinical pilot study in 15 individual patients. J Cancer Res Clin Oncol. 2003;129:521-30.
68. Noda K, Ohashi Y, Sugimori H, et al. Phase III double-blind randomized trial of radiation therapy for stage IIIb cervical cancer in combination with low- or high-dose Z-100: treatment with immunomodulator, more is not better. Gynecol Oncol. 2006;101:455-63.